AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel — iHeart Business Talk Radio’s “The Trader’s Network” on December 2nd, 2014
Live Interview Airs on The Trader’s Network Radio Show, Hosted by Michael Yorba, 9:00pm ET/6:00pm PT/8:00pm CT
ALACHUA, FL–(Dec 2, 2014) – AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel — iHeart Business Talk Radio’s “The Trader’s Network” Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen’s unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company’s strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.
Date: December 2, 2014
Start Time: 9:00pm ET | 6:00pm PT | 8:00pm CT (U.S.)
Network: Clear Channel – iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia.www.clearchannel.com.
About the Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am – 7:30am and 2pm – 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.
Cautionary Statement Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499